The role of cinacalcet in treating secondary hyperparathyroidism.
Compelling evidence exists to use cinacalcet as a primary therapy for the treatment of secondary HPT in patients requiring dialysis. The benefits of directly lowering PTH in combination with improving calcium-phosphorus homeostasis provide a means to better achieve the K/DOQI bone guidelines. Cinacalcet is usually well tolerated and safe to use, making it possible to treat a wide range of patients with varying levels of disease severity. The ideal course of action for this novel therapy is for nephrology nurses and renal dietitians to use a team approach in the management of secondary HPT.
Brommage
Deborah
D
Winthrop-University Hospital Dialysis Center, Mineola, NY, USA.
Gallgano
Cynthia
C
D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D000069449:Cinacalcet; D017326:Clinical Trials, Phase III as Topic; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000150:complications*; D009281:Naphthalenes / Q000494:pharmacology / Q000627:therapeutic use*; D010281:Parathyroid Hormone / Q000097:blood; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D006435:Renal Dialysis / Q000009:adverse effects*; D016896:Treatment Outcome; D014807:Vitamin D / Q000627:therapeutic use
D009281:Naphthalenes; D010281:Parathyroid Hormone; D014807:Vitamin D; D000069449:Cinacalcet